Compare Hims and Hers Health Inc (HIMS) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs T Rowe Price Group Inc — how do they compare? Hims and Hers Health Inc trades at $32.91 (market cap $7.57B), while T Rowe Price Group Inc trades at $117.63 (market cap $25.14B). The key difference: T Rowe Price Group Inc is far larger — about 3.3× Hims and Hers Health Inc's market cap, and T Rowe Price Group Inc pays a 4.43% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| HIMS | TROW | |
|---|---|---|
Market Cap | $7.57B | $25.14B |
Sector | Health | Financials |
52-Week High | $66.18 | $120.16 |
52-Week Low | $14.52 | $86.19 |
Enterprise Value | $7.95B | $21.85B |
Dividend Yield | — | 4.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $32.70, down 0.43% on the day, with a bearish technical signal despite bullish moving averages. The company reported $2.35 billion in 2025 revenue but swung to a projected net loss for 2026, with mixed quarterly earnings results. Recent news highlights executive changes and anticipation for Q2 2026 results on August 10, 2026, with analyst sentiment leaning toward a Buy consensus.
The outlook is cautious due to profitability concerns and high valuation multiples, but growth opportunities in weight-loss and telehealth services offer potential. Key risks include execution challenges and regulatory scrutiny. The stock presents a speculative growth play with a consensus price target of $33.57, slightly above the current price.
T. Rowe Price (TROW) trades at $116.345, down 0.86% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 2026 earnings that beat expectations, with revenue growth from $7.1B in 2024 to $7.3B in 2025 and a net income margin of 28.28%. Recent news highlights the launch of an active crypto ETF and AUM reaching $1.89 trillion in June 2026.
The outlook for TROW is mixed; valuation ratios like a P/E of 12.59 suggest potential undervaluation, but analyst consensus is cautious with a hold-heavy rating. Key risks include equity outflows and market volatility, while opportunities lie in diversified AUM growth and innovation. The stock's performance hinges on sustaining profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
